These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2907 related articles for article (PubMed ID: 28455219)

  • 1. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
    Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
    Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
    Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
    Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer.
    Zhao X; Chen Q; Liu W; Li Y; Tang H; Liu X; Yang X
    Int J Nanomedicine; 2015; 10():257-70. PubMed ID: 25565818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer.
    Wang Q; Zou C; Wang L; Gao X; Wu J; Tan S; Wu G
    Acta Biomater; 2019 Aug; 94():469-481. PubMed ID: 31141733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-sensitive polymeric nanoparticles of mPEG-PLGA-PGlu with hybrid core for simultaneous encapsulation of curcumin and doxorubicin to kill the heterogeneous tumour cells in breast cancer.
    Yuan JD; ZhuGe DL; Tong MQ; Lin MT; Xu XF; Tang X; Zhao YZ; Xu HL
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):302-313. PubMed ID: 29301415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft copolymer nanoparticles with pH and reduction dual-induced disassemblable property for enhanced intracellular curcumin release.
    Zhao J; Liu J; Xu S; Zhou J; Han S; Deng L; Zhang J; Liu J; Meng A; Dong A
    ACS Appl Mater Interfaces; 2013 Dec; 5(24):13216-26. PubMed ID: 24313273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
    Cui T; Zhang S; Sun H
    Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailored design of multifunctional and programmable pH-responsive self-assembling polypeptides as drug delivery nanocarrier for cancer therapy.
    Wang TW; Yeh CW; Kuan CH; Wang LW; Chen LH; Wu HC; Sun JS
    Acta Biomater; 2017 Aug; 58():54-66. PubMed ID: 28606810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional hybrid nanoconstructs facilitate intracellular localization of doxorubicin and genistein to enhance apoptotic and anti-angiogenic efficacy in breast adenocarcinoma.
    Shukla RP; Dewangan J; Urandur S; Banala VT; Diwedi M; Sharma S; Agrawal S; Rath SK; Trivedi R; Mishra PR
    Biomater Sci; 2020 Mar; 8(5):1298-1315. PubMed ID: 31903460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
    Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
    Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-Responsive prodrug nanoparticles based on a sodium alginate derivative for selective co-release of doxorubicin and curcumin into tumor cells.
    Gao C; Tang F; Gong G; Zhang J; Hoi MPM; Lee SMY; Wang R
    Nanoscale; 2017 Aug; 9(34):12533-12542. PubMed ID: 28819666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
    Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
    J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
    Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
    Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cRGDyK modified pH responsive nanoparticles for specific intracellular delivery of doxorubicin.
    Qiu L; Hu Q; Cheng L; Li L; Tian C; Chen W; Chen Q; Hu W; Xu L; Yang J; Cheng L; Chen D
    Acta Biomater; 2016 Jan; 30():285-298. PubMed ID: 26602824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance.
    Zhang D; Kong YY; Sun JH; Huo SJ; Zhou M; Gui YL; Mu X; Chen H; Yu SQ; Xu Q
    Int J Nanomedicine; 2017; 12():2081-2108. PubMed ID: 28356731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.
    Kucuksayan E; Bozkurt F; Yilmaz MT; Sircan-Kucuksayan A; Hanikoglu A; Ozben T
    Sci Rep; 2021 Jun; 11(1):13027. PubMed ID: 34158544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
    Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
    Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer.
    Zhang Y; Yang C; Wang W; Liu J; Liu Q; Huang F; Chu L; Gao H; Li C; Kong D; Liu Q; Liu J
    Sci Rep; 2016 Feb; 6():21225. PubMed ID: 26876480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 146.